Trial Profile
A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 21 Jul 2019 Planned End Date changed from 1 Jul 2022 to 1 Feb 2023.
- 21 Jul 2019 Planned primary completion date changed from 1 Feb 2022 to 1 Oct 2022.
- 21 Jul 2019 Status changed from not yet recruiting to recruiting.